Fennec Pharmaceuticals (FENC) - Quarterly EPS earnings growth

Official company branding of Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals (FENC) is scaling revenue through outsourced manufacturing and a network of oncology centers to minimize costs. The business's protected status is driven by the priority of pediatric therapy, while financial stability ensures the coverage of all obligations. The quarterly EPS trend reflects fundamental profit momentum, with the 147.20 mark serving as the current indicator of the earnings per share trend.

Fennec Pharmaceuticals Inc. (FENC) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Fennec Pharmaceuticals

- market value and analyst target forecast:
Price Chart Fennec Pharmaceuticals Inc.|FENC - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Fennec Pharmaceuticals Inc|FENC - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Fennec Pharmaceuticals|FENC - Total Stockholders' Equity|Market Value to Book Value Ratio fennecpharma.com|FENC - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Fennec Pharmaceuticals|FENC - Long-Term Liabilities to Capital|Short-Term Debt to Capital Fennec Pharmaceuticals|FENC - Company Total Indebtedness|Debt to Book Value Fennec Pharmaceuticals Inc|FENC - Long-Term Debt|Company Current Liabilities Fennec Pharmaceuticals|Quick Liquidity Indicator fennecpharma.com
- earnings and market multiples details:
FENC - Profit After Payment of Taxes|Projected Future Earnings Fennec Pharmaceuticals|FENC - Company Value to Net Income|Forward P/E Multiple Fennec Pharmaceuticals Inc|FENC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fennec Pharmaceuticals Inc|FENC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Fennec Pharmaceuticals|FENC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months fennecpharma.com|FENC - Earnings per share trend in current year|Expected earnings per share growth for next year Fennec Pharmaceuticals
Fundamental company analysis:Fennec Pharmaceuticals Inc., FENC
Manufactured product of Fennec

Fennec Pharmaceuticals' narrow specialization in pediatric oncology makes its revenue dependent on insurance reimbursements. An analysis of the relative quarterly change in EPS allows for tracking the impact of these market constraints on profitability. This metric measures the percentage shift in net income per share compared to the previous period. Positive momentum confirms the scalability of the therapy despite competition. Steady growth of this indicator testifies to the financial stability of the business.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Heron - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Coherus Biosciences|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla Corp BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology Holdings)|CTXR (citiuspharma.com) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com